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Abstract: The product of the interferon-stimulated gene C19orf66, Shiftless (SHFL), restricts human
immunodeficiency virus replication through downregulation of the efficiency of the viral gag/pol
frameshifting signal. In this study, we demonstrate that bacterially expressed, purified SHFL can
decrease the efficiency of programmed ribosomal frameshifting in vitro at a variety of sites, including
the RNA pseudoknot-dependent signals of the coronaviruses IBV, SARS-CoV and SARS-CoV-2,
and the protein-dependent stimulators of the cardioviruses EMCV and TMEV. SHFL also reduced
the efficiency of stop-codon readthrough at the murine leukemia virus gag/pol signal. Using size-
exclusion chromatography, we confirm the binding of the purified protein to mammalian ribosomes
in vitro. Finally, through electrophoretic mobility shift assays and mutational analysis, we show that
expressed SHFL has strong RNA binding activity that is necessary for full activity in the inhibition of
frameshifting, but shows no clear specificity for stimulatory RNA structures.
Keywords: ribosome; frameshift; readthrough; Shiftless; virus
1. Introduction
Recoding events during mRNA translation have been described in the expression of
many viral and cellular genes and include such phenomena as programmed ribosomal
frameshifting (PRF), stop codon readthrough (RT), selenocysteine insertion and transla-
tional bypassing [1,2]. In –1 PRF, mRNA signals induce ribosomes to slip back by one
nucleotide (nt) into an overlapping open reading frame (ORF) and to continue translation,
generating a fusion protein of upstream and downstream ORFs [3–10]. First described as
the mechanism by which the Gag-Pol polyprotein of the retrovirus Rous sarcoma virus
(RSV) is expressed from overlapping gag and pol ORFs [11], related –1 PRF signals have
been documented in many other viruses of clinical, veterinary and agricultural impor-
tance [1,5]. PRF has also been increasingly recognized in cellular genes of both prokaryotes
and eukaryotes as well as in other replicating elements, such as insertion sequences and
transposons [12–14]. –1 PRF is associated with diverse biological processes, including
the expression of viral replicases (e.g., HIV reverse transcriptase [15]), bacteriophage tail
fibers [16] and the Escherichia coli (E. coli) DNA polymerase γ subunit [17]. It is also
involved in the regulation of mRNA stability [18,19], the cell cycle [14], mammalian devel-
opment [20], human paraneoplastic disorders [21] and genetic diseases [22].
Central to –1 PRF is the interaction of the ribosome with a stimulatory mRNA structure
(a stem-loop or pseudoknot) that promotes frameshifting at the slippery sequence (Figure 1).
How these RNA structures act is incompletely understood, but by presenting an unusual
topology [3,4,23–25], they likely confound an intrinsic unwinding activity of the ribosome
with consequent effects on the elongation cycle and frame maintenance [26–28]. Indeed,
kinetic analyses in bacterial systems indicate that stimulatory RNAs can impair movements
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of the ribosomal small subunit (30S) head, delaying the dissociation of EF-G, and the
release of tRNA from the ribosome [29–31]. The propensity of the stimulatory RNA to
sample multiple folded conformations has also been linked to –1 PRF efficiency [32–35]
and an effect of co-translational folding of the nascent peptide can also modulate the
process [36]. Mechanistic insights into –1 PRF are also being sought through studies of
two highly efficient PRF signals whose activity requires the participation of trans-acting
proteins (Figure 1). In the cardioviruses encephalomyocarditis virus (EMCV) and Theiler’s
murine encephalitis virus (TMEV), frameshifting within the 2B gene requires viral protein
2A [37–39], and in the arterivirus porcine reproductive and respiratory syndrome virus
(PRRSV), production of the nsp2TF protein by frameshifting is mediated by a complex of
the viral protein nsp1β and host poly[C] binding protein (PCPB) [40–42].
Recently, an interferon (IFN)-stimulated gene (ISG) was identified whose encoded
product, Shiftless (SHFL), is able to restrict human immunodeficiency virus (HIV) replica-
tion through downregulation of the efficiency of the viral gag/pol frameshifting signal [43].
SHFL is the first identified cellular factor that acts as a repressor of –1 PRF and the first ex-
ample of an ISG that targets a translational recoding process. It is a 33 kDa protein encoded
in an eight-exon gene (C19orf66) located on genomic region 19p13.2. The protein has also
been referred to as C19orf66 in studies of its role in restricting Kaposi’s sarcoma-associated
herpes virus (KSHV) [44], hepatitis C virus (HCV) [45] and Zika virus (ZIKV) [46]; by
virtue of its ability to repress the yield of Dengue virus (DENV), it has also been named
RyDEN [47] and interferon-regulated antiviral gene (IRAV) [48]. In virus replication and
–1 PRF reporter gene assays in cells, SHFL was found to be a broad-spectrum inhibitor
of –1 PRF [43] but did not greatly affect replication of the retrovirus murine leukemia
virus (MuLV), suggesting that the protein may not inhibit pseudoknot-dependent RT, a
related recoding process employed in the expression of the MuLV Gag-Pol polyprotein [49].
The extent of inhibition of –1 PRF found in these experiments was typically 50–60%, a
magnitude of reduction known to suppress replication of a variety of viruses employing
PRF [50–54]. Through polysome profiling, SHFL was found to associate with actively
translating ribosomes, and co-immunoprecipitated with proteins from both the small (eS31)
and large (uL5) subunits in a binding screen of individual ribosomal proteins. SHFL was
also able to bind to a short RNA containing the HIV-1 PRF signal, although the affinity and
specificity of the interaction were not reported.
In this paper, we demonstrate that bacterially expressed, purified SHFL can reduce
the efficiency of both PRF and RT in in vitro translation assays and confirm binding of the
protein to mammalian ribosomes in vitro. Through electrophoretic mobility shift assays
and mutational analysis, we show that the expressed protein has the strong RNA binding
activity necessary for full activity in the inhibition of recoding but shows no obvious
specificity for stimulatory RNA structures.
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Figure 1. Modulators of programmed –1 ribosomal frameshifting. Cartoon drawings of ribosomes encountering sites of
PRF. Stimulators: (A) HIV stem-loop; (B) IBV pseudoknot; (C) SARS-CoV-2 pseudoknot (SARS-CoV sequence identical in
the region shown except for an (A) to (C) transversion in loop 3 (L3) as indicated); (D) PRRSV complex of virus (nsp1β)
and host protein (PCBP); (E) Cardiovirus (EMCV) stimulatory RNA complexed with viral 2A protein. Repressor: (F) SHFL
shown bound at the HIV-1 signal. Purple and cyan ovals represent eRF1 and eRF3 (in complex).
2. Materials and Methods
2.1. Plasmids
Assessment of in vitro recoding efficiencies employed the reporter plasmids p2luc [55]
and pDluc [56], with viral sequences inserted between the Renilla and firefly luciferase
coding sequences as detailed in Table 1. Plasmid pHis-SHFL was cloned as follows. The
human SHFL cDNA sequence was codon-optimized for E. coli expression and synthesized
de novo (Epoch Life Sciences, Sugar Land, TX, USA). This was subsequently amplified
by PCR (F 5′ AATTCATATGTCTCAGGAAGGTGTGGA 3′; R 5′ AATTGGATCCTTAT-
TACTCGCGGGGCCCGCCCTCCT 3′) and cloned into Nde I/BamH 1-cut pOPT3H to
introduce an N-terminal His6 tag.
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Table 1. Sequences of recoding signals employed (recoding site underlined).
































2.2. Protein Expression and Purification
Recombinant protein was produced in E. coli BL21 (DE3) pLysS cells grown by shaking
(210 rpm) in 2×TY broth supplemented with 100 µg/mL ampicillin and 12.5 µg/mL
chloramphenicol (37 ◦C). Expression was induced at A600 of ~0.6 with 0.5 mM isopropyl
β-D-1-thiogalactopyranoside (IPTG; 21 ◦C, 16 h). Cells were harvested by centrifugation
(4000× g, 4 ◦C, 20 min), washed in ice-cold phosphate-buffered saline (PBS) and stored at
−20 ◦C. Protein was prepared from 6L culture. Per liter, cell pellets were resuspended in
50 mL ice-cold lysis buffer (50 mM Tris (HCl) pH 7.9, 500 mM NaCl, 30 mM imidazole,
0.05% w/v Tween-20 supplemented with 50 µg/mL DNase I and EDTA-free protease
inhibitors) and lysed using a cell disruptor (Constant Systems, Daventry, UK; 24 kPSI, 4 ◦C).
The lysate was clarified by centrifugation (39,000× g, 30 min, 4 ◦C) and incubated (1 h,
4 ◦C) with 0.5 mL Ni-NTA agarose beads (Qiagen, UK) that had been pre-equilibrated in
the same buffer. Beads were washed three times by centrifugation (600× g, 10 min, 4 ◦C)
and resuspension in 50 mL wash buffer (50 mM Tris (HCl) pH 7.9, 500 mM NaCl, 30 mM
imidazole). Washed beads were pooled, transferred to a gravity column, and protein was
eluted dropwise with 50 mM Tris (HCl) pH 7.9, 300 mM NaCl, and 300 mM imidazole.
Fractions containing SHFL were pooled and dialyzed into 20 mM Tris (HCl) pH 7.9, 300 mM
NaCl, 1.0 mM DTT (10 K molecular weight cut-off (MWCO), 4 ◦C, 16 h). To remove nucleic
acids, dialysate was loaded onto a 5 mL HiTrap Heparin column (GE Healthcare, UK) at
2.0 mL/min, washed with two column volumes buffer (25 mM Tris (HCl) pH 7.9, 300 mM
NaCl, 1.0 mM DTT) and eluted with a 0–100% gradient of high-salt buffer (25 mM Tris (HCl)
pH 7.9, 1.0 M NaCl, 1.0 mM DTT) over 20 column volumes. SHFL-containing fractions
were pooled and concentrated using an Amicon® Ultra centrifugal filter unit (10K MWCO,
4000× g) prior to further purification by size exclusion chromatography (Superdex 200
10/300 column; 25 mM Tris (HCl) pH 7.9, 300 mM NaCl, 1.0 mM DTT). Purity was assessed
by 4–20% gradient SDS-PAGE, and protein identity was verified by mass spectrometry.
Purified protein was concentrated (~6.5 mg/mL, 187 µM), snap-frozen in liquid nitrogen
and stored at −80 ◦C.
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2.3. In Vitro Translation
Frameshift reporter plasmids were linearized with EcoR I (p2luc) or Fsp I (pDluc),
and capped run-off transcripts generated using T7 RNA polymerase. Messenger RNAs
were translated in nuclease-treated rabbit reticulocyte lysate (RRL) extracts (Promega)
programmed with ~50µg/mL template mRNA. Typical reactions were of 10 µL volume
and composed of 90% (v/v) RRL, 20 µM amino acids (lacking methionine) and 0.2 MBq
[35S]-methionine. When added, SHFL was diluted where necessary in dilution buffer (DB)
(5 mM Tris (HCl) pH 7.5, 100 mM KCl, 1 mM DTT, 0.05 mM EDTA, 5% glycerol) and added
to reactions in 1 µL final volume. Reactions were incubated for 1 h at 30 ◦C and stopped
by the addition of an equal volume of 10 mM EDTA, 100 µg/mL RNase A, followed by
incubation at room temperature for 20 min. Samples were prepared for SDS-PAGE by
the addition of 10 volumes of 2× sample buffer, boiled for 4 min and resolved on 12%
gels. Dried gels were exposed to a Cyclone Plus Storage Phosphor Screen (PerkinElmer,
Waltham, MA, USA), the screen scanned using a Typhoon TRIO Variable Mode Imager (GE
Healthcare, UK) in storage phosphor autoradiography mode, and bands were quantified
using ImageQuantTMTL software (GE Healthcare, UK). The calculations of frameshifting
efficiency (% –1FS) took into account the differential methionine content of the two products
and % –1FS was calculated as = 100 × (IFS/MetFS)/(IS/MetS + IFS/MetFS). In the formula,
the number of methionines in the stop and –1 FS products are denoted by MetS and MetFS;
while the densitometry values for the same products are denoted by IS and IFS, respectively.
Calculations of readthrough efficiency followed the same procedure.
2.4. Immunoblotting
Aliquots of fractions from size exclusion chromatography were denatured in an equal
volume of 2X sample buffer and heated to 95 ◦C for 5 min. Proteins were separated on
10–20% SDS-PAGE gradient gels (Novex; Thermo Fisher Scientific, Waltham, MA, USA)
and transferred to nitrocellulose membranes. These were blocked for 60 min with 5%
powdered milk (Marvel) in PBS + 0.1% Tween-20 (PBST) and probed at 4 ◦C overnight with
primary antibodies (mouse anti-RPL4 (clone 4A3, Merck, UK, WH0006124M1 at 1:1000);
mouse anti-RPS6 (clone A16009C, BioLegend, UK, 691802 at 1:1000); rabbit anti-SHFL
(HPA042001, Atlas Antibodies at 1:500)). Membranes were washed in PBST before being
incubated in the dark with an IRDye-conjugated secondary antibody in PBST. Blots were
scanned using an Odyssey infrared imaging system (Li-Cor).
2.5. Electrophoretic Mobility Shift Assay (EMSA)
Short, 32P-labelled template RNAs (48-102 nt) containing individual recoding signals
were prepared by T7 transcription of linearized plasmid templates. SHFL dilutions were in
dilution buffer (DB) (5 mM Tris (HCl) pH 7.5, 100 mM KCl, 1 mM DTT, 0.05 mM EDTA,
5% glycerol) and added to reactions (10 µL final volume) alongside EMSA buffer (10 mM
HEPES (NaOH) pH 7.6, 150 mM KCl, 2 mM MgCl2, 1 mM DTT, 0.5 mM ATP, 5% glycerol,
100 µg/mL porcine tRNA, 10U RNase inhibitor per mL), after which the radiolabeled
probe was introduced. After incubation at 37 ◦C for 15 min, samples were loaded promptly
onto 10% acrylamide non-denaturing gels (acrylamide:bisacrylamide ratio 10:1) and run at
175 V at room temperature until free and bound RNA species were resolved. Gels were
fixed for 15 min in 10% acetic acid, 10% ethanol, dried and exposed to X-ray film.
3. Results
3.1. Effect of Purified SHFL on Ribosomal Frameshifting and Readthrough In Vitro
Wang and colleagues [43] studied the involvement of SHFL in –1 PRF in tissue cul-
ture cells by measuring the levels of relevant virus proteins in infected cells expressing
SHFL, or by transfection of frameshift reporter plasmids. We wished to determine if the
purified protein had anti-frameshifting activity in vitro. Codon-optimized, N-terminally-
His6-tagged SHFL was expressed in E. coli BL21 (DE3) pLysS, purified and used to sup-
plement in vitro translation reactions (rabbit reticulocyte lysate (RRL)) programmed with
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frameshift-reporter mRNAs (see Materials and Methods). SDS-PAGE of the purified pro-
tein confirmed its integrity (Figure 2), and its identity was confirmed by mass spectroscopy
(Mr = 33,109 Da, 60% peptide coverage). The published capacity to bind 80S ribosomes [43]
was verified by size-exclusion chromatography (Figure 2B,C). In in vitro translation ex-
periments, we employed the HIV-1 signal as a positive control (following [43]), and an
assortment of other –1 PRF signals, including the RNA pseudoknot-dependent signals
of the betacoronavirus SARS-CoV and the gammacoronavirus infectious bronchitis virus
(IBV), and the protein-dependent signals of EMCV and TMEV (Figure 3). At all signals
tested, SHFL addition led to a reduction in –1 PRF, varying from a modest effect at the HIV
gag/pol signal (reduced from 4.5 to ~3%; Figure 3) to a more substantial reduction at the
protein-dependent site of TMEV (from 53% to 12%). A version of SHFL with reduced RNA
binding capacity (mutant M1, see below) was also expressed and tested in comparison
to the wild-type protein at the TMEV signal (Figure 3). As can be seen, the addition of
the mutant protein had little effect on –1 PRF. We also tested the capacity of SHFL to
modulate stop codon readthrough, using the signal derived from the gag/pol overlap of
the retrovirus murine leukemia virus (MuLV). We found that SHFL was indeed able to
decrease readthrough efficiency, four-fold in RRL (Figure 3).
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Figure 2. Characterization of purified SHFL and association with mammalian 80S ribosomes. (A) SDS-
PAGE analysis of purified SHFL. (B) Size-exclusion chromatogram of purified SHFL (37 µM). Frac-
tions across the peak were analyzed by immunoblot for SHFL. (C) As (B) following the incubation
of SHFL (18 µM) with RRL 80S ribosomes (1 µM; purified according to [57]). Fractions across the
peak were immunoblotted for SHFL and ribosomal proteins uL4 and eS6. Note, in panel (C), the
absorbance readings are dominated by 80S ribosomes.
3.2. RNA Binding Activity of SHFL
How SHFL affects recoding processes is not well understood but may involve specific
recognition of the stimulatory RNAs. To assess RNA binding, we carried out electrophoretic
mobility shift assays (EMSAs) using 5′-end-labeled transcripts (48-102 nt in length) contain-
ing the frameshift-stimulatory RNA of IBV (both the minimal PK (IBVmin) with shortened
L3 [58] and the wild-type pseudoknot (IBVmax)), the MuLV RT signal [54] or a variant
destabilized in PK stem 1 (MuLV S1) and a control transcript derived from the SARS-CoV-2
antigenome with no obvious recoding signal (control). As seen in Figure 4, protein-RNA
complexes were formed in all cases at similar SHFL concentrations, except for IBVmin,
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where the binding was noticeably weaker. Increasing SHFL concentration generally led
to a concomitant stepwise reduction in mobility of the SHFL-RNA complexes, although
the fastest mobility complex persisted somewhat with the MuLV RNA. Overall, these data
indicate that SHFL has strong RNA binding activity but appears to lack obvious specificity
to sites of –1 PRF, and probably, RT. Computational analysis of the SHFL protein sequence
reveals a number of putative functional domains within a predicted secondary structure
comprising 13 α-helixes and four β-strands (Figure 5; [47]). Using PHYRE2 [59], we iden-
tified several arginine residues within a putative zinc-finger domain that are potentially
involved in nucleic acid binding. We prepared three derivatives of SHFL with alanine
substitutions at various positions (mutant 1, R131A/R136A; mutant 2, R131A/R133A;
and mutant 3, R131A/R133A/R136A), expressed and purified the proteins, and tested
their capacity to inhibit SARS-CoV-2 PRF in RRL and to bind RNA in EMSAs using the
IBVmax template (Figure 6; Supplementary Figure S1). We found a correlation between
RNA binding and the inhibition of PRF, with the wild-type protein most active in each case
and M3 the least active. These experiments indicate that RNA binding is required for full
activity in the inhibition of PRF.




Figure 3. Inhibition by SHFL of PRF and RT in vitro. RNAs derived from recoding reporter plasmids were translated in RRL
in the presence of the indicated concentration of His-tagged SHFL or SHFL-M1. The addition of only water (W) or SHFL
dilution buffer (DB) is also indicated. The products were resolved by 12% SDS-PAGE and visualized by autoradiography.
14C molecular size markers were also run on the gel (M). IFC represents an in-frame control translation of an mRNA in
which the two reading frames are placed in-frame by the addition of a single nucleotide immediately downstream of
the slippery sequence (see Table 1). Proteins generated by ribosomes that do not frameshift (stop) or that enter the −1
reading frame (PRF), or read through a stop codon (RT) are arrowed. In the EMCV and TMEV panels, the addition of the
trans-activator protein 2A is shown by lane underlining.
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Figure 4. SHFL binds to RNA in EMSA assays. EMSA analysis of binding of SHFL to short (48-
102 nt) 32P-labeled in vitro transcripts containing a recoding signal, or a control RNA (as indicated
on the left). After incubation at 37 ◦C for 15 min, reactions were loaded onto 10% non-denaturing
polyacrylamide gels and, following electrophoresis, the gels were fixed, dried and subjected to
autoradiography. The radiolabeled RNA was at 10 nM in each reaction. R represents a lane loaded
with RNA only. In lanes marked 0, the RNA was incubated alone with SHFL dilution buffer (see
Materials and Methods). Destabilized base-pairs in MuLV S1 are in black.
, , x FOR PEER REVIEW 11 of 17  
 
 
Figure 5. Predicted domains and features in SHFL. (A) Plot of predicted disorder probability vs. residue
number (DISOPRED2 [60]), indicating a predominantly globular fold. (B) Prediction of secondary structural
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elements (PSIPRED [61]). (C) Annotated domain diagram of SHFL. The central CxxC motifs are
highly conserved among family members (Pfam UPF0515). Other regions of interest include a
putative zinc-finger domain, E-rich acidic domain, coiled-coil domain, nuclear localization sequence
(NLS) and experimentally determined region necessary for interaction with PABP [47]. The locations
of R131, R133 and R136 mutated in this study are indicated.
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Figure 6. Activity of mutant derivatives of SHFL. (A) An mRNA derived from pDluc/SARS-CoV-2
was translated in RRL in the presence of the indicated concentrations of His-tagged SHFL (WT) or
mutant derivative (M1, M2, M3). The addition of SHFL dilution buffer (DB) only is indicated. The
products were resolved and analyzed as detailed in the legend to Figure 3. (B) EMSA analysis of bind-
ing of SHFL (WT) or mutant derivative (M1, M2, M3) to a 32P-labeled in vitro transcript containing
the IBVmax PK. The EMSA was carried out and processed as detailed in the legend of Figure 4. The
original gels from which the panels of this Figure are derived as shown in Supplementary Figure S1.
4. Discussion
In this study, we show that recombinant SHFL can decrease the efficiency of pro-
grammed ribosomal frameshifting in vitro at a variety of sites of viral –1 PRF and can
also have an impact on programmed stop-codon readthrough at the MuLV signal. We
demonstrate that the expressed protein has RNA binding activity, identify arginine residues
that contribute to this, and show that RNA binding is necessary for full activity in the
inhibition of recoding.
In recoding assays in RRL, the effect of SHFL varied, with the recombinant protein
invoking reductions in the region of 0.5 to four-fold. We noted a general inhibitory effect of
SHFL on overall translation at higher levels of SHFL, a possible consequence of its ribosome
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binding capacity, which could compromise elongation. This inhibitory effect was observed
only at concentrations of SHFL higher than those having an effect on recoding, however,
indicating the specificity of SHFL action in inhibiting recoding events (densitometry of the
protein bands of Figure 3 is shown in the Supplementary Table S1). Nevertheless, subtle
effects on elongation, coupled with minor differences between related recoding signals and
their reporter mRNA contexts, might account for the observed differences in the magnitude
of the SHFL effect. In addition, the relative levels of potential co-factors in RRL extracts
might influence the activity of SHFL at some sites. The effect of SHFL at the HIV-1 signal
was modest, but in line with that measured in transfected cells, with frameshifting at the
HIV-1 and SARS-CoV-2 signals known to be reduced to some 60–70% of wild-type levels
in HEK293 cells [62].
In EMSAs, SHFL bound a variety of short RNA templates (apparent Kd~500 nM) with
no obvious specificity for templates containing a functional stimulatory RNA. In these
experiments, there was a trend towards decreased mobility of the RNA-protein complex as
the relative concentration of SHFL was increased, potentially signifying the generation of
higher-order complexes with multiple copies of SHFL on the RNA. Alternatively, SHFL
has been proposed to self-associate via interactions between putative C-terminal coiled-coil
domains [43], therefore, some higher-order complexes may involve dimeric species. In the
MuLV EMSA, the slower mobility complexes appeared alongside a more persistent band
that may be a 1:1 complex. Further work will be required to ascertain whether this reflects
a specific binding event. The observed impaired binding to the minimal IBV pseudoknot
(Figure 4) can be accounted for by the compact nature of the pseudoknot on this template,
which lacks extensive regions of single-stranded RNA (this variant of the IBV stimulatory
pseudoknot has a much shorter loop 3, reduced from 32 to 8 nt [58]). These data are
consistent with the studies of Balinsky and colleagues [48], where SHFL was shown to
bind more strongly to single-stranded RNA than to double-stranded DNA. SHFL variants
with mutations in arginine residues potentially involved in nucleic acid binding showed
reduced activity in both RNA binding and inhibition of PRF. Further characterization of
these mutants (M1, M2, M3) will be required to understand the molecular basis of the deficit.
We note, for example, that the M1 mutant had no obvious activity against the protein-
dependent TMEV signal (Figure 3) but was able to impair SARS-CoV-2 frameshifting, albeit
at higher concentrations than the wild-type protein (Figure 6). This may reflect mechanistic
differences in –1 PRF between the two signals.
How SHFL downregulates –1 PRF is uncertain. Wang and colleagues [43] have sug-
gested that the protein binds to ribosomes when they are in a non-canonical rotated state
(the postulated frameshifting state) [29–31,63], leading to ribosome pausing. Subsequently,
stalled ribosomes are thought to be removed from the template in a process involving
recruitment of the release factor complex (eRF1-eRF3) leading to the generation of a prema-
ture termination product (Figure 1). The data described in the present work are supportive
of this model, with SHFL acting most likely through an interaction with ribosomes rather
than via specific binding to the stimulatory RNAs. A capacity to bind RNA is essential for
maximal activity, but whether this reflects a necessity to bind to rRNA or mRNA, or both,
remains to be determined. The role of release factors in the pathway of SHFL action is also
uncertain. In the present study, we cannot easily discriminate proteins derived from natural
termination at the upstream cistron of the reporter mRNA (the Stop product on the gels)
from any that may arise from drop-off at the recoding site, as the sites are too close together
on the mRNA. However, the observation that SHFL can reduce programmed RT in vitro is
consistent with a role for SHFL in recruiting release factors. It has been shown previously
that expressed SHFL was not found to have a substantial effect on MuLV replication in
culture [43]. Based on our previous work [54], the ~four-fold reduction in readthrough we
see in RRL might be expected to noticeably reduce MuLV replication in culture. However,
differences in experimental systems might account for this discrepancy.
SHFL is an important antiviral—and likely broadly antipathogenic—ISG discovered
relatively recently [47] and is, as yet, not extensively studied [43–48,64]. How it exerts
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its effect in different viral contexts is not well established. In Zika virus, SHFL degrades
viral protein NS3 [46], whereas, in DENV, which also lacks a documented –1 PRF signal, it
may act by interfering with viral mRNA translation through the formation of an inhibitory
complex [47] with polyA binding protein C1 (PABPC1; known to bind to the DENV 3′
UTR [65]) and La autoantigen motif-related protein 1 (LARP1). Balinski and colleagues [48]
alternatively hypothesize that DENV replication is inhibited through degradation of viral
mRNA, through the recruitment of replication complexes to processing (P) bodies following
interactions between SHFL and cellular factors including MOV10 (a RISC complex RNA
helicase). In HCV, SHFL restricts the formation of the viral replication organelle, likely
through interactions with stress granule and P-body components [45]. In KSHV, SHFL
restricts early gene expression and particle release, perhaps also through interactions
with PABPC1 and LARP1. Along with its role in inhibiting –1 PRF and RT, these studies
reveal the capacity of SHFL to associate with a variety of cellular factors and to mediate
its antiviral activity through different pathways. The activity of recombinant SHFL in
reducing recoding efficiencies in RRL does not rule out an involvement of co-factors, as
homologs of some known interacting partners [e.g., PABPC1] are present in this extract.
Further work will be required to decipher the molecular mechanisms of SHFL action in
virus-infected cells.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/v13071230/s1, Figure S1: Original gels of Figure 6, Table S1: Intensities for stop and recoded
species from Figure 3.
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